Blood cancers, Cell type, Hodgkin lymphoma, Lymphoma
Results
Phase 3
This trial looked at 3 different combinations of chemotherapy for Hodgkin lymphoma. This trial was supported by Cancer Research UK.
Doctors often treat Hodgkin lymphoma with a combination of chemotherapy called ABVD. This contains the drugs doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine.
When this trial was done, doctors thought that giving more drugs may be helpful. So the people in this trial either had standard ABVD treatment, or one of two newer combinations of chemotherapy. One was a combination of 7 drugs called ChlVPP/EVA (the ‘hybrid’ regime). The other was a combination of 8 drugs calledChlVPP/PABIOE (the ‘alternating’ regime). Doctors called these ‘multi drug regimes’ or MDRs.
The aim of this trial was to find out if either of the MDRs are better than ABVD for Hodgkin lymphoma.
Recruitment start: 1 February 1998
Recruitment end: 30 September 2001
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Peter Johnson
Cancer Research UK
Medical Research Council (MRC)
National Institute for Health Research Cancer Research Network (NCRN)
This is Cancer Research UK trial number CRUK/95/017.
Last reviewed: 12 January 2016
CRUK internal database number: 956
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
